Richard Wayne Joseph

Richard Wayne Joseph

Auto-generated profile, based on publicly available information

Richard Wayne Joseph

Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in The Lancet
Verified
Journal Article
Closed access
JRJonathan E Rosenberg
Jonathan E Rosenberg
JHJean Hoffman-Censits
Jean Hoffman-Censits
TPTom Powles
Tom Powles
MHMichiel S van der Heijden
Michiel S van der Heijden
ABArjun V Balar
Arjun V Balar
RDRobert Dreicer
Robert Dreicer

11 July 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
OHOmid Hamid
Omid Hamid
Caroline RobertCaroline Robert
Caroline Robert
ADAdil Daud
Adil Daud
FHF. Stephen Hodi
F. Stephen Hodi
WHWen-Jen Hwu
Wen-Jen Hwu
ARAntoni Ribas
Antoni Ribas
The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma. We administered lambrolizumab intravenously at a dose of 10 mg per kilogram of body weight every 2 or 3 weeks or 2 mg per kilogram every 3 weeks in patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not. Tumor responses were assessed every 12 weeks. A total of 135 patients with advanced melanoma were treated. Common adverse events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were low grade. The confirmed response rate across all dose cohorts, evaluated by central radiologic review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was 38% (95% confidence interval [CI], 25 to 44), with the highest confirmed response rate observed in the cohort that received 10 mg per kilogram every 2 weeks (52%; 95% CI, 38 to 66). The response rate did not differ significantly between patients who had received prior ipilimumab treatment and those who had not (confirmed response rate, 38% [95% CI, 23 to 55] and 37% [95% CI, 26 to 49], respectively). Responses were durable in the majority of patients (median follow-up, 11 months among patients who had a response); 81% of the patients who had a response (42 of 52) were still receiving treatment at the time of analysis in March 2013. The overall median progression-free survival among the 135 patients was longer than 7 months. In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. (Funded by Merck Sharp and Dohme; ClinicalTrials.gov number, NCT01295827.)

1 January 2017 in The Lancet
Verified
Journal Article
Closed access
ABArjun V Balar
Arjun V Balar
MGMatthew D Galsky
Matthew D Galsky
JRJonathan E Rosenberg
Jonathan E Rosenberg
TPThomas Powles
Thomas Powles
DPDaniel P Petrylak
Daniel P Petrylak
DBDean F Bajorin
Dean F Bajorin

1 September 2014 in The Lancet
Verified
Journal Article
Closed access
Caroline RobertCaroline Robert
Caroline Robert
ARAntoni Ribas
Antoni Ribas
JWJedd D Wolchok
Jedd D Wolchok
FHF Stephen Hodi
F Stephen Hodi
OHOmid Hamid
Omid Hamid
ADAdil Daud
Adil Daud

19 April 2016 in JAMA
Verified
Journal Article
Open access
PDF file
ARAntoni Ribas
Antoni Ribas
OHOmid Hamid
Omid Hamid
ADAdil Daud
Adil Daud
FHF. Stephen Hodi
F. Stephen Hodi
JWJedd D. Wolchok
Jedd D. Wolchok
Caroline RobertCaroline Robert
Caroline Robert
Research from JAMA — Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

1 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FHF. Stephen Hodi
F. Stephen Hodi
WHWen-Jen Hwu
Wen-Jen Hwu
RKRichard Kefford
Richard Kefford
JWJeffrey S. Weber
Jeffrey S. Weber
ADAdil Daud
Adil Daud
JWJedd D. Wolchok
Jedd D. Wolchok
Purpose: We evaluated atypical response patterns and the relationship between overall survival and best overall response measured per immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) in patients with advanced melanoma treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods: Patients received pembrolizumab 2 or 10 mg/kg every 2 weeks or every 3 weeks. Atypical responses were identified by using centrally assessed irRC data in patients with ≥ 28 weeks of imaging. Pseudoprogression was defined as ≥ 25% increase in tumor burden at week 12 (early) or any assessment after week 12 (delayed) that was not confirmed as progressive disease at next assessment. Response was assessed centrally per irRC and RECIST v1.1. Results: Of the 655 patients with melanoma enrolled, 327 had ≥ 28 weeks of imaging follow-up. Twenty-four (7%) of these 327 patients had atypical responses (15 [5%] with early pseudoprogression and nine [3%] with delayed pseudoprogression). Of the 592 patients who survived ≥ 12 weeks, 84 (14%) experienced progressive disease per RECIST v1.1 but nonprogressive disease per irRC. Two-year overall survival rates were 77.6% in patients with nonprogressive disease per both criteria (n = 331), 37.5% in patients with progressive disease per RECIST v1.1 but nonprogressive disease per irRC (n = 84), and 17.3% in patients with progressive disease per both criteria (n = 177). Conclusion: Atypical responses were observed in patients with melanoma treated with pembrolizumab. Based on survival analysis, conventional RECIST might underestimate the benefit of pembrolizumab in approximately 15% of patients; modified criteria that permit treatment beyond initial progression per RECIST v1.1 might prevent premature cessation of treatment.